<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904176</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-058</org_study_id>
    <nct_id>NCT00904176</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects</brief_title>
  <official_title>Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine that Dapagliflozin has no effect on the
      pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin when dapagliflozin is
      coadministered with warfarin. Also, that Dapagliflozin has no effect on the PK of digoxin
      when dapagliflozin is coadministered with digoxin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs</measure>
    <time_frame>216 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of dapagliflozin on the PK of R-warfarin, when warfarin and dapagliflozin are coadministered in healthy subjects (Cohort 1)</measure>
    <time_frame>16 time points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects</measure>
    <time_frame>16 time points</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin + Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin + Digoxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablets, Oral, 20 mg, followed by 10 mg, Single Dose</description>
    <arm_group_label>Dapagliflozin + Warfarin</arm_group_label>
    <arm_group_label>Dapagliflozin + Digoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Tablets, Oral, 25 mg, Single Dose</description>
    <arm_group_label>Dapagliflozin + Warfarin</arm_group_label>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Tablets, Oral, 0.25, Single Dose</description>
    <arm_group_label>Dapagliflozin + Digoxin</arm_group_label>
    <arm_group_label>Digoxin</arm_group_label>
    <other_name>Lanoxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

          -  Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²

          -  Women who are not of childbearing potential (ie, who are postmenopausal or surgically
             sterile) and men, ages 18 to 45

        Exclusion Criteria:

          -  WOCBP include any female who has experienced menarche and who has not undergone
             successful surgical sterilization (hysterectomy, bilateral tubal ligation, or
             bilateral oophorectomy) or is not postmenopausal

          -  Any significant acute or chronic medical illness or relevant trauma (e.g. history of
             chronic hypertension, bacterial endocarditis, hemorrhagic stroke, motor vehicle
             accident resulting in significant head trauma or internal injuries)

          -  History of important arrhythmias as determined by the Investigator, including but not
             limited to ventricular fibrillation, ventricular tachycardia, A-V block,
             Wolff-Parkinson-White Syndrome, and sinus bradycardia (defined in this study as heart
             rate &lt; 50 bpm based on vital signs and ECG performed within 21 days of Study Day 1)

          -  History or evidence of abnormal bleeding or coagulation disorder (e.g., history of
             prolonged bleeding during dental procedures, pregnancy delivery, previous surgery or
             injury) and/or having a first degree relative under 50 years of age with a history of
             abnormal bleeding or coagulation disorder per patient's report

          -  History of unexplained syncope

          -  Presence of external hemorrhoids with signs of rectal bleeding on physical exam

          -  Positive fecal occult blood (FOB), using the Hemoccult Sensa® assay (or equivalent),
             or hematuria (more than trace), unless deemed not clinically significant by the
             Investigator and Medical Monitor at screening or dosing

          -  Platelet count &lt; 150,000 cells/µL at screening or dosing

          -  INR or aPTT values above the upper limit of normal (ULN) at screening or dosing

          -  Hemoglobin or hematocrit &lt; LLN at screening or dosing

          -  Abnormal urinalysis at screening or dosing (repeat urinalysis may be allowed for
             positive hematuria in women)

          -  Glucosuria at screening or dosing

          -  Abnormal liver functions tests (ALT, AST or total bilirubin &gt; 10% above ULN) at
             screening or dosing

          -  History of diabetes mellitus

          -  History of heart failure

          -  History of renal insufficiency

          -  History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal
             mycotic infections

          -  Positive urine screen for drugs of abuse either at screening or before dosing

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1,
             -2 antibody

          -  Protein C or Protein S deficiency

          -  History of allergy to SGLT2 inhibitors or related compounds

          -  History of allergy to warfarin or related compounds

          -  History of allergy to digoxin or related compounds

          -  Prior exposure to dapagliflozin within 3 months of Day -1

          -  Exposure to any investigational drug or placebo within 4 weeks of Day -1

          -  Use of any prescription drugs within or over-the-counter acid controllers or vitamin K
             containing products within 4 weeks prior to study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pra International</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3648&amp;filename=MB102-058_redacted%20_CSR%20_synopsis.pdf</url>
    <description>MB102-058_redacted _CSR _synopsis</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2009</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

